Royal Bank Of Canada initiated coverage on shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in a research note released on Thursday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $14.00 price target on the stock.

A number of other equities analysts also recently commented on KPTI. ValuEngine downgraded Karyopharm Therapeutics from a hold rating to a sell rating in a report on Thursday, May 25th. Cantor Fitzgerald set a $18.00 price objective on Karyopharm Therapeutics and gave the stock a buy rating in a report on Saturday, June 24th. Robert W. Baird restated an outperform rating and issued a $15.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, July 4th. Zacks Investment Research upgraded Karyopharm Therapeutics from a hold rating to a buy rating and set a $11.00 price objective on the stock in a report on Thursday, July 6th. Finally, Jefferies Group LLC restated a buy rating and issued a $16.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, July 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $15.67.

Shares of Karyopharm Therapeutics (KPTI) opened at 11.00 on Thursday. The firm’s 50-day moving average is $9.28 and its 200-day moving average is $9.87. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63. The stock’s market capitalization is $518.52 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, hitting analysts’ consensus estimates of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. The company’s revenue for the quarter was down 95.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.84) EPS. On average, equities research analysts anticipate that Karyopharm Therapeutics will post ($2.68) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/18/karyopharm-therapeutics-inc-kpti-receives-new-coverage-from-analysts-at-royal-bank-of-canada.html.

Several large investors have recently made changes to their positions in KPTI. Teachers Advisors LLC increased its holdings in Karyopharm Therapeutics by 15.0% during the 4th quarter. Teachers Advisors LLC now owns 41,436 shares of the company’s stock worth $389,000 after purchasing an additional 5,419 shares during the last quarter. Nationwide Fund Advisors increased its holdings in Karyopharm Therapeutics by 175.8% during the 1st quarter. Nationwide Fund Advisors now owns 56,527 shares of the company’s stock worth $726,000 after purchasing an additional 36,031 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Karyopharm Therapeutics by 103.9% during the 1st quarter. Russell Investments Group Ltd. now owns 74,882 shares of the company’s stock worth $962,000 after purchasing an additional 38,158 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Karyopharm Therapeutics by 114.6% during the 1st quarter. Wells Fargo & Company MN now owns 43,606 shares of the company’s stock worth $560,000 after purchasing an additional 23,284 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Karyopharm Therapeutics by 61.7% during the 1st quarter. Bank of New York Mellon Corp now owns 181,602 shares of the company’s stock worth $2,332,000 after purchasing an additional 69,315 shares during the last quarter. Institutional investors and hedge funds own 58.97% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.